Lung cancer is the most common cancer worldwide – and one of the most prevalent types is non small-cell lung cancer (NSCLC). As the disease continues to grow and evolve, so does the need for testing.
The cobas® EGFR Mutation Test v2 (CE-IVD) is the first oncology assay from Roche Molecular Diagnostics to utilize plasma in addition to tumour tissue as the sample type, thus removing common barriers to molecular testing. With clear, actionable results, the cobas® EGFR Mutation Test v2 (CE-IVD) gives clinicians the information needed to make confident treatment decisions.
Discover the potential of the cobas® EGFR Mutation Test v2 to help empower better cancer care.
Download our infographic for a quick reference on the facts and figures of the cobas® EGFR Mutation Test v2.
Fill in the form below to receive email communication about the new cobas® EGFR Mutation Test v2.
Gain more detailed knowledge of EGFR testing on our regularly updated publications page.EGFR Publications »